Protective molecule, ACE2, also proving its worth in diabetic patients

May 16, 2012

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients.

Gavin Oudit, a researcher with the Faculty of Medicine & Dentistry, and his colleagues at the University of Florida, found that lab models that lacked ACE2 had worse cardiovascular complications related to diabetes.

"We show that if you take ACE2 away, they [lab models of diabetes] do very poorly," said Oudit. "It worsened their function and their vascular function."In patients, if you have high levels of ACE2 in your vascular reparative cells you do not get diabetic complications, even if your diabetic control is very poor."

The study was funded by the National Institutes of Health, Alberta Innovates – Health Solutions and the Canadian Institutes of Health Research.

Oudit's related studies have also looked at another major organ affected by diabetes – the kidneys. ACE2 proved protective in these organs, as well.

"Diabetes is the world's most common cause of blindness and renal failure, so this work is very important," he said.

The next step is to analyze human blood samples from Edmonton's patient population to see the effects of ACE2 in diabetics. The researchers will screen the blood of both Type 1 and Type 2 since they think it's relevant in both.

"We're hoping to show that patients that lack ACE2 are more susceptible to diabetic complications," said Oudit.

Human recombinant ACE2, which is a pure form of this enzyme, is currently moving into Phase 2 clinical trials as a treatment for lung disease. The hope is that its use could then be extended as a pharmaceutical to treat diabetic patients so they can avoid cardiovascular, renal or eye disease.

Oudit's work is published in the May 11th edition of the journal Circulation Research with an accompanying editorial.

Explore further: Research aims to prevent diabetic kidney failure

Related Stories

Research aims to prevent diabetic kidney failure

November 5, 2011

The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.

Recommended for you

Post-biotics may help shield obese from diabetes

April 20, 2017

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood ...

Diabetes continues its relentless rise

April 13, 2017

(HealthDay)—Two new studies on diabetes deliver good and bad news, but the overall message is that the blood sugar disease remains a formidable public health burden.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.